Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$113.95 USD

113.95
75,481

+0.09 (0.08%)

Updated Oct 8, 2024 10:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.

Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug

by Zacks Equity Research

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.

Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment

by Zacks Equity Research

Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 2025.

Company News for Jul 20, 2022

by Zacks Equity Research

Companies in The News Are: BA, NVS, TFC, IBM

Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura

by Zacks Equity Research

Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.

Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.

Novartis (NVS) Announces Positive Data on Oncology Drug

by Zacks Equity Research

Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.

The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J

by Zacks Equity Research

Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel Backs Updated COVID Jabs, EU Nod for SNY, MRK Drugs

by Kinjel Shah

An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.

Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma

by Zacks Equity Research

Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.

Sheraz Mian headshot

Q2 Earnings Season Preview and Featured Analyst Reports for J&J, AMD & Union Pacific

by Sheraz Mian

Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).

Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML

by Zacks Equity Research

The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.

Kinjel Shah headshot

Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates

by Kinjel Shah

The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).

Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion

by Zacks Equity Research

Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.

Precision BioSciences' (DTIL) Stock Up This Week: Here's Why

by Zacks Equity Research

Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.

Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals

by Zacks Equity Research

Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Amgen (AMGN) Olpasiran Lowers Lipoprotein Levels in Phase II

by Zacks Equity Research

Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers the body's production of apolipoprotein(a), a key component of Lp(a) which increases the risk of cardiovascular events.

Roche's (RHHBY) Evrysdi Gets FDA Nod for Label Extension

by Zacks Equity Research

The FDA approves a label expansion of Roche's (RHHBY) SMA drug Evrysdi to include less than two-month old babies with SMA.

Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah

by Zacks Equity Research

Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.

The Zacks Analyst Blog Highlights Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group

by Zacks Equity Research

Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group have been included in this Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Bank of America, Novo Nordisk, & Novartis

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Novo Nordisk A/S (NVO), and Novartis AG (NVS).

Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA

by Zacks Equity Research

Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.

Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition

by Zacks Equity Research

Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.

Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss

by Zacks Equity Research

Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.